ArticleJournal for immunotherapy of cancer2026

First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.

Kristoffer Staal Rohrberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.